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Abstract
Background: Hepatic lesions often present diagnostic connundrums with conventional MR techniques. Hepatobiliary phase
contrast-enhanced imaging with gadoxetic acid can aid in the characterization of such lesions. However, quantitative
measures describing late-phase enhancement must be assessed relative to their accuracy of hepatic lesion
classification. Purpose: To compare quantitative parameters in gadoxetic acid contrast-enhanced dynamic and
hepatobiliary phase imaging versus apparent diffusion coefficients in hepatic lesion characterization.
Material and Methods: 57 patients with focal hepatic lesions on gadoxetic acid MR were included. Lesion enhancement at
standard post-contrast time points and in the hepatobiliary phase (HB; 15 and 25 minutes post-contrast) was assessed via
calculation of contrast (CR) and enhancement ratios (ER). Apparent diffusion coefficient (ADC) values were also obtained.
Values for these parameters were compared among lesions and ROC analyses performed. Results: HB enhancement was
greatest with FNH and adenomas. HB ER parameters but not HB CR could distinguish HCC from benign entities (0.9 ER ROC
AUC versus 0.5 CR ROC AUC). There was no statistically significant difference found between the 15 and 25 minutes HB time
points in detection of any lesion (p.0.4). ADC values were statistically significantly higher with hemangiomas (p,0.05)
without greater accuracy in lesion detection relative to HB phase parameters.
Conclusion: Hepatobiliary phase gadoxetic acid contrast-enhanced MR characterizes focal hepatic lesions more accurately
than ADC and conventional dynamic post-contrast time point enhancement parameters. ER values are generally superior to
CR. No discernible benefit of 25 minute versus 15 minute delayed imaging is demonstrated.
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Introduction
Conventional dynamic contrast-enhanced MRI (cDCE-MRI)
suffers limitations in characterization of focal hepatic lesions
secondary to overlapping enhancement characteristics or variable
appearances of lesions [1,2]. This shortcoming of cDCE-MRI has
been improved through the utilization of additional hepatic MR
imaging techniques such as diffusion-weighted imaging (DWI) [3]
and hepatocyte-specific contrast agents [4].
Diffusion-weighted imaging (DWI) also aids in identification
and classification of hepatic lesions [3,5–7]. DWI allows analysis of
tissue proton Brownian motion, providing a quantitative measure
of such motion by an apparent diffusion coefficient (ADC).
Characterization of a focal hepatic lesion by ADC values has been
shown useful so far in the setting of detection of metastatic disease
[8] and in the characterization of hepatic hemangiomas and cysts
[3]. Previous studies utilizing supraparamagnetic iron oxide
contrast-enhanced MR demonstrated the benefit of the addition
of diffusion weighted images in HCC detection and evaluation
[9,10].
Gadoxetic acid disodium (Eovist; Bayer Healthcare Pharma-
ceuticals; Gd-EOB-DTPA) is a gadolinium chelate MR contrast
agent with 50% hepatobiliary excretion which allows improved
characterization of hepatic lesions. Specifically, lesions containing
functioning hepatocytes, such as focal nodular hyperplasia (FNH),
demonstrate enhancement on delayed (i.e. hepatobiliary) phase
imaging with gadoxetic acid, relative to lesions without functioning
hepatocytes such as hepatocellular carcinomas (HCC) or metas-
tases [11].
In the daily clinical routine some cases, especially the
differentiation of solitary hepatic masses such as adenoma,
HCC, and FNH, remain diagnostic conundrums. In such cases,
quantitative assessments of DWI and contrast-enhancement
parameters may aid radiologists in establishing a diagnosis.
However, several questions remain. The first is which quantified
measures of Gd-EOB-DTPA hepatobiliary phase enhancement
allow for accurate differentiation of hepatic lesions. Specifically, it
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must be determined which of the two measurements reported in
the literature for CA uptake, ER or CR is more reliable [12].
Second, Gd-EOB-DTPA is more costly than standard contrast
agents, so the question of whether quantitative late phase imaging
significantly outperforms early dynamic imaging is relevant. Third,
DWI is an important modalit which does not require contrast
administration, a fact particularly relevant given the nephrogenic
systemic fibrosis discussion. Quantitative measurements for the
differentiation of HCCs, adenomas, and FNHs should thus be
analyzed.
Therefore, the aim of this present study is to evaluate the
relative accuracy of Gd EOB-DTPA contrast-enhanced early
dynamic and hepatobiliary phase imaging as well as quantified
diffusion weighted imaging in the characterization of four major
focal hepatic lesions (HCC, FNH, adenomas, hemangiomas).
Materials and Methods
Ethics Statement
The local institutional review board of the University Medical
Center Mannheim approved and oversaw this study. All patient
studies were performed at that institution. Informed consent was
obtained. This clinical investigation was conducted according to
the principles of the Declaration of Helsinki.
Study population
A total of 178 consecutive patients referred for Gd-EOB-DTPA
MR imaging of the liver as part of routine clinical practice at the
University Medical Center Mannheim from January 2008–
February 2011 were included in this institutional review board
(IRB) approved retrospective study analysis. Informed written
consent was obtained. Inclusion criteria were the presence of one
or more focal hepatic lesions—specifically focal nodular hyper-
plasia, hepatic adenoma, hemangioma or hepatocellular carcino-
ma. Of the patients examined, 57 (26 men, 31 women, mean age
53.6614.5 years) met the criteria for inclusion into the study. Of
these, 21 hemangiomas, 18 hepatocellular carcinomas (11 of
which were evaluated in cirrhotic livers), 10 hepatic adenomas,
and 8 cases of focal nodular hyperplasia were assessed. Of these, 1
hemangioma and 2 hepatocellular carcinomas, were confirmed
histopathologically at our hospital. The other lesions were
confirmed by the clinical course of disease as established by
imaging and clinical followup, the latter assessed by review of the
medical record. In most cases, followup multi-phase MRI or CT
examinations were available for followup assessment of lesions. In
cases where lesions were also followed by ultrasound, these results
were incorporated into the establishment of the final clinical
diagnosis. The mean follow-up time period was 794 days; the
mean number of follow-up exams was 7. Especially for benign
lesions like hemangiomas, which are not routinely biopsied,
diagnosis was based on taking all MR sequences into account for
lesion assessment. If more than one lesion was imaged, then only
the largest lesion was evaluated in the analysis. This approach was
chosen as the focus of the study was on lesion characterization
through enhancement characteristics and not on lesion detection.
Exclusion criteria were incomplete examinations as well as lesions
Figure 1. Mean enhancement ratios over time. Mean enhancement ratios not demonstrating statistically significant differences are enclosed
within a single shape (i.e. circle, square, or triangle). Those not enclosed by the same shape demonstrate statistically significant differences in mean
enhancement ratios for a given time point (p,0.05).
doi:10.1371/journal.pone.0061898.g001
Gadoxetic Acid Enhanced MRI versus DWI
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in which lesion size was too small to allow accurate ROI analysis.
Among the 121 patients excluded were those with cholangiocarci-
nomas (n = 4), liver cysts (n = 25), metastases (n = 8), cirrhotic
nodules (n = 30) as well as those with incomplete/inadequate scans
or unconfirmed lesions as per the criteria stated above (n = 54).
MR protocol
All patients underwent a MR-exam with a standardized
protocol on a single 1.5T MR-system (MAGNETOM AVANTO
32676, Siemens Healthcare Sector, Erlangen, Germany). Pre-
contrast single-shot echo planar diffusion weighted imaging was
obtained utilizing a product EPI-sequence with b values of 0, 50,
400, and 800 s/mm2 (TR/TE 8260.4/75 ms, acquisition time
3:45 min:sec, matrix 1926150, FoV 3796308, parallel imaging
acceleration factor 2) during free breathing. ADC-values were
calculated by the scanner using a monoexponential fitting based
on all four measured b-values. Pre- and post-contrast T1-weighted
images following Gd-EOB-DTPA administration were then
obtained. The Gd-EOB-DTPA dose was standardized at
0.025 mmol/kg bw. A 6 channel body-array coil was utilized in
combination with 6 elements of the spine matrix coil. 3D Volume-
Interpolated Breathhold Examination (VIBE) sequences (TR/TE
5.5/1.93 ms, FA 30u, acquisition time 21.1 sec, matrix 3846188,
FoV 3706265, slice thickness 3 mm, voxel size 1.061.463 mm3,
parallel imaging factor 2) were used to acquire pre-contrast, early-
phase dynamic extracellular and hepatobiliary phase imaging. For
early-phase dynamic contrast-enhanced imaging with Gd-EOB-
DTPA, VIBE sequences were obtained at 25 seconds (arterial
phase), 60 seconds (portal venous phase), and 80 seconds (venous
phase). Hepatobiliary phase imaging was obtained at 15 (HB1) and
25 minutes (HB2) following contrast injection.
Image evaluation
Region of interest (ROI) analysis was performed on the
acquired MR images by a single observer blinded to study
methodology and aims. Circular ROIs were drawn on an offline
workstation MacPro (Apple, Cupertino, CA) running OsiriX
(OsiriX 3.7.1, The OsiriX Foundation, Geneva, Switzerland) on
the pre- and post-contrast T1w images and ADC maps. The
maximum size of the ROIs was fitted to the size of a given lesion.
Care was taken that the ROI size did not exceed the edges of the
lesion to avoid partial volume influence on the measured signal
intensity. Areas of necrosis were likewise avoided in ROI
placement. An additional ROI similar in size was drawn in a
region of adjacent normal-appearing hepatic parenchyma. Care
was taken to avoid inclusion of hepatic arterial or (portal-)venous
structures. ROI data was collected along with the final diagnosis in
Microsoft Excel.
Contrast-enhancement parameters
Two parameters have been proposed for the assessment of
enhancement with hepatocyte-specific MR contrast agents [12].
The enhancement ratio (ER) is calculated at a given post-contrast
phase as [13]:
Figure 2. Mean contrast ratios over time. Mean contrast ratios not demonstrating statistically significant differences are enclosed within a single
shape (i.e. circle, square, or triangle). Those not enclosed by the same shape demonstrate statistically significant differences in mean contrast ratios
for a given time point (p,0.05).
doi:10.1371/journal.pone.0061898.g002
Gadoxetic Acid Enhanced MRI versus DWI
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Figure 3. Mean hepatic parenchymal signal intensities over time. Mean parenchymal signal measures not demonstrating statistically
significant differences are enclosed within a single shape (i.e. circle, square, or triangle). Those not enclosed by the same shape demonstrate
statistically significant differences in mean parenchymal signal for a given time point (p,0.05).
doi:10.1371/journal.pone.0061898.g003
Figure 4. Mean lesion ADC values for each lesion type. * denotes p-values less than 0.05.
doi:10.1371/journal.pone.0061898.g004
Gadoxetic Acid Enhanced MRI versus DWI
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ER~ Signallesionpost{contrast{Signallesionpre{contrast
 
=Signallesionpre{contrast
Enhancement ratios were calculated for each lesion, for each post-
contrast time point evaluated. The contrast ratio (CR) has also
been suggested as a measure of late-phase hepatobiliary enhance-
ment and was calculated for each time point evaluated as follows
[12]:
CR~
Signallesionx
Signalparechyma x
where x denotes a given pre- or post-contrast phase of imaging.
Statistical analysis
Mean and standard errors about the mean were calculated for
CR and ER measures at every time point post-contrast for each
lesion type in SPSS (Statistical Processing for the Social Sciences v
13 SPSS Inc, IBM, Armok, NY). ADC values and signal values of
normal hepatic parenchyma were similarly computed. One-way
analysis of variance (ANOVA) measures were performed to test for
differences among the lesions with respect to ER, CR, ADC
values, and hepatic parenchymal signal. A Levene statistic to test
for variance homogeneity was obtained. Multiple comparison tests
were performed for each parameter to test for differences among
the lesions depending on variance homogeneity for a given lesion.
A Least Squares Differences test was utilized for multiple
comparisons when variances were homogeneous and the Dunnett
T3 in cases when variances were heterogeneous. P-values less than
0.05 were considered statistically significant for all comparisons.
ROC analyses assessing ER and CR were performed for each
type of lesion at all available time points as well as for the ADC
values. These analyses assessed whether a lesion was or was not of
a certain type (i.e. a hemangioma or not). The analysis was
performed in MedCalc for Windows version 11.6 (MedCalc
Software, Mariakerke, Belgium). The area under each ROC curve
(AUC) was obtained, and these values compared to the AUC of a
diagonal curve (AUC=0.5).
Comparisons of ROC measures generated by ER and CR
values at both hepatobiliary phase time points were also performed
utilizing MedCalc. Since the distinction between a diagnosis of
HCC and not HCC is the most fundamental in this evaluation, the
cutoff point which maximized combined sensitivity and specificity
was identified on the ROC curve (the upper-most, left-most point)
with MedCalc. For each lesion type, an additional comparison was
Figure 5. ROC curves generated from contrast ratio (CR) and enhancement ratio (ER) parameters. These were used for identification of
hepatocellular carcinoma (HCC), focal nodular hyperplasia (FNH), hemangiomas, and adenomas in the pre-contrast, arterial, portal venous (PV), and
venous phases. * reflects statistically significant (p,0.05) differences relative to a random test (AUC=0.5). Parameters leading to the highest absolute
AUC values are boxed; these parameters were utilized for comparisons with hepatobiliary phase imaging.
doi:10.1371/journal.pone.0061898.g005
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analogously made between the early dynamic imaging phase with
gadoxetic acid (pre-contrast, arterial, venous or portal venous)
yielding the greatest absolute AUC value (utilizing either CR or
ER) versus the hepatobiliary phase parameter with the greatest
AUC value. Finally, hepatobiliary phase ER and CR AUC values
were compared to those generated from ADC values for each
lesion type.
The ability of hepatobiliary phase images (using both ER and
CR values) and ADC values to differentiate between pairs of
lesions was analogously compared. This was done utilizing pair-
wise analyses of the 4 different lesion types (i.e. HCC, adenoma,
hemangioma, FNH) resulting in a total of 6 comparisons. AUC
values with ER, CR, and ADC values were compared to evaluate
the ability of these measures to distinguish between pairs of lesions.
The area under the ROC curves for each lesion were compared
for hepatobiliary phase imaging and ADC values utilizing
MedCalc as above. This was performed utilizing both CR and
ER parameters. Early dynamic phase parameters were not utilized
for the pairwise comparisons due to the decrease in statistical
power attributable to making such a large number of comparisons
and because the ROC analyses described in the previous
paragraph had preliminarily shown equivalence or superiority of
hepatobiliary phase versus early dynamic phase imaging.
Results
Mean comparisons
The mean values for contrast (CR) and enhancement (ER)
ratios of each lesion are depicted in Figures 1 and 2. The general
trends were toward statistically significantly higher CR and ER
with FNH and adenoma in HB1 and HB2 as compared to the
other lesions.
Adenomas and FNHs could be differentiated with statistical
significance from HCCs utilizing ER in HB1 and HB2. The mean
(6 standard deviation) ER of adenomas was 1.960.4 in HB1 and
2.560.7 in HB2 (p,0.05). The ER of FNHs was 2.160.4 in HB1
and 2.560.6 in HB 2 (p,0.05). HCC demonstrated lower HB1
and HB2 ER than all other lesions (mean HB1 ER=0.960.3,
mean HB2 ER=1.460.7; p,0.001).
CR of FNH (1.160.2 at 15 minutes and 1.160.2 at 25 minutes)
was statistically significantly higher than that of all other lesions
(p,0.01; for 15 and 25 minutes, respectively: adenoma 20.860.2
and 0.860.2; hemangioma 20.560.1 and 0.560.2; HCC
20.760.2 and 0.760.2). Adenomas demonstrated significantly
higher HB1 and HB2 CR than hemangiomas (p,0.01), but not
HCC (p= 0.1).
In the hepatobiliary phases, parenchyma of HCC livers
demonstrated statistically significantly lower signal than all other
livers (p,0.05) as illustrated in Figure 3. As shown in Figure 4,
mean ADC values were higher with hemangiomas than with all
other lesions (p,0.05).
ROC analysis and determination of cut-off values
ROC curves for the differentiation of lesions by the early
dynamic phase parameters (arterial – portal-venous – venous
phase) are illustrated in Figure 5. The early dynamic phase-
parameter combinations with the highest absolute AUC values
were venous ER for HCCs (AUC=0.8), venous CR for FNH
(AUC=0.9), pre-contrast CR values for hemangiomas
(AUC=0.9), and portal venous CR for adenomas (AUC=0.8).
Figure 6. ROC curves for ADC values. These reflect the ability to detect hepatocellular carcinoma (HCC), focal nodular hyperplasia (FNH),
hemangiomas, and adenomas. * reflects statistically significant (p = 0.05) differences relative to a random test (AUC=0.5).
doi:10.1371/journal.pone.0061898.g006
Gadoxetic Acid Enhanced MRI versus DWI
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ROC curves for lesion differentiation via ADC values are provided
in Figure 6. Only hemangiomas were accurately identified by
ADC values (AUC=0.8, p,0.001).
The ROC AUC for hepatobiliary phase imaging is provided in
Table 1 and depicted graphically in Figure 7. Comparing the
assessed hepatobiliary phase enhancement parameters, ER was
more accurate than CR in distinguishing HCC from non-HCC
Figure 7. ROC curves generated from contrast ratio (CR) and enhancement ratio (ER) parameters. These were used for identification of
hepatocellular carcinoma (HCC), focal nodular hyperplasia (FNH), hemangiomas, and adenomas at hepatobiliary phase time points 15 (HB1) and
25 minutes post-contrast. * reflects statistically significant (p,0.05) differences relative to a random test (AUC= 0.5) and *** reflects statistically
significant reflects p-values less than 0.001. AUC values statistically significantly greater than others are boxed.
doi:10.1371/journal.pone.0061898.g007
Figure 8. Representative images illustrating a case of hepatocellular carcinoma on fat saturated T2-weighted images (top left), ADC
maps (top middle), and post-contrast images in the arterial (top right), portal venous (bottom left), venous (bottom middle), and
hepatobiliary phases (15 minutes post-contrast; bottom right).
doi:10.1371/journal.pone.0061898.g008
Gadoxetic Acid Enhanced MRI versus DWI
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lesions (p,0.02), but CR was more accurate than ER at
distinguishing hemangiomas from other lesions (p,0.001). No
other statistically significant differences in the accuracy of CR and
ER were found. In no case was the accuracy, as determined by
AUC measures, of the 25 minute delayed hepatobiliary phase
imaging statistically significantly different from that of the
15 minute delayed hepatobiliary imaging (p = 0.6). Examples of
each type of pathology assessed in this study are provided in
Figures 8–11.
Comparing early dynamic versus hepatobiliary phase imaging,
venous phase ER was less accurate than HB1 ER in the detection
of HCC (p,0.01). In particular, specificity increased from 61.5%
to 87% utilizing HB1 ER versus venous phase ER, while sensitivity
remained constant at 94.4% utilizing a cut of values of 0.16. No
other differences were found (p= 0.5).
Only in identification of hemangiomas, HB1 and HB2 ER were
less accurate than were ADC values (p,0.005). No other
significant differences were found between hepatobiliary phase
parameters and ADC values (p = 0.3).
The AUC values for pair-wise lesion comparisons are provided
in Table 2. Overall, ADC values allowed accurate differentiation
between hemangiomas and all other lesions (p,0.05). However, in
no case was the accuracy of ADC values statistically significantly
greater than that of hepatobiliary phase enhancement parameters.
Neither adenomas and HCC, nor FNH and HCC could be
differentiated solely using ADC values, whereas hepatobiliary
phase enhancement parameters allowed accurate differentiation.
No statistically significant differences were seen between 15 and
25 minutes post-contrast hepatobiliary phase imaging for any pair-
wise comparison. Hepatobiliary ER were statistically significantly
more accurate than CR in the differentiation of adenomas versus
HCC. No other statistically significant differences were found.
Based on the ROC analysis, optimal cutoff values were
determined for differentiation between HCC and benign lesions
for hepatobiliary phase enhancement parameters and ADC values.
These are provided in Table 3. Maximum sensitivity and
specificity values obtained for quantitative conventional and
hepatobiliary phase enhancement parameters for the detection
of each lesion type are detailed in Table 4.
Figure 9. Representative images illustrating a case of focal nodular hyperplasia on fat saturated T2-weighted images (top left), ADC
maps (top middle), and post-contrast images in the arterial (top right), portal venous (bottom left), venous (bottom middle), and
hepatobiliary phases (15 minutes post-contrast; bottom right).
doi:10.1371/journal.pone.0061898.g009
Figure 10. Representative images illustrating a case of a hemangioma on fat saturated T2-weighted images (top left), ADC maps
(top middle), and post-contrast images in the arterial (top right), portal venous (bottom left), venous (bottom middle), and
hepatobiliary phases (15 minutes post-contrast; bottom right).
doi:10.1371/journal.pone.0061898.g010
Gadoxetic Acid Enhanced MRI versus DWI
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Discussion
Accurate characterization of focal hepatic lesions is imperative
due to resulting alterations in therapy and can obviate the risk of
unnecessary biopsy or surgeries in the case of benign lesions.
Likewise accurate identification of malignant lesions facilitates
prompt treatment. MRI has emerged as a valuable tool in this
regard, particularly with respect to hepatocyte-specific MR
contrast agents and diffusion-weighted imaging. The present study
examines focal hepatic lesion characterization with the latter two
approaches. The results herein indicate that quantitative evalua-
tions of hepatobiliary phase imaging with gadoxetic acid are useful
in the characterization of several focal hepatic lesions, more so
than ADC values or early dynamic phase imaging (i.e. pre-
contrast, arterial, portal venous, and venous phase). In particular,
HCC identification was improved with hepatobiliary phase ER
measures compared with early-phase dynamic imaging.
Both CR and ER have been suggested as potential quantitative
measures for hepatobiliary-phase enhancement with hepatocyte-
specific contrast agents [12], and qualitative evaluations of
hepatobiliary enhancement characteristics have relied on criteria
analogous to CR [14]. No consensus currently exists as to whether
CR or ER is a more reliable measure, a question addressed herein
for the first time to the knowledge of the authors. This study finds
that the principle drawback of the CR values are the inability to
distinguish HCC from non-HCC lesions, relative to the ER
parameter. This most likely relates to the diminished hepatobiliary
phase parenchymal enhancement in patients with HCC, a finding
previously shown in cirrhotic livers [15]. CR values for HCC are
as a result elevated, making them similar to those values seen with
adenomas. HCC ERs, on the other hand, remain decidedly lower
than those of any other lesion. We thus conclude that CR values
are less effective than ER values for identification of HCC;
although, CR measures are more accurate in other specific
situations such as distinguishing adenomas from FNH. However,
the most critical decision in terms of the immediate therapeutic
consequences for the patient, is to identify HCCs and to
differentiate them from non-HCCs lesions. Thus, we would
Figure 11. Representative images illustrating a case of hepatic adenoma on fat saturated T2-weighted images (top left), ADC maps
(top middle), and post-contrast images in the arterial (top right), portal venous (bottom left), venous (bottom middle), and
hepatobiliary phases (15 minutes post-contrast; bottom right).
doi:10.1371/journal.pone.0061898.g011
Table 1. Area under the ROC curve for hepatobiliary phase
(HB) imaging.
Lesion Contrast Ratio Enhancement Ratio
HB1 HB2 HB1 HB2
HCC 0.54 0.55 0.9¤ 0.84¤
FNH 0.93¤ 0.93¤ 0.87¤ 0.84¤
Hemangioma 0.89¤ 0.88¤ 0.51 0.55
Adenoma 0.70* 0.67 0.79¤ 0.8¤
*denotes p-value,0.05 relative to a random test (AUC= 0.5).
¤denotes p-value,0.001 relative to a random test (AUC= 0.5).
Bolded values denote AUC values significantly less than non-bolded values in a
given row.
HB1, 2 =Hepatobiliary phase 1 and 2 (15 and 25 minutes post-contrast).
HCC=Hepatocellular carcinoma.
FNH= Focal Nodular Hyperplasia.
doi:10.1371/journal.pone.0061898.t001
Table 2. Differentiation Between Pairs of Liver Lesions.
Enhancement Ratio Contrast Ratio
ROC AUC HB 1 HB 2 HB 1 HB 2 ADC
FNH –
Adenoma
0.65 0.55 0.76* 0.8* 0.58
FNH –
Hemangioma
0.88* 0.9* 1 0.99 0.83*
FNH – HCC 0.97* 0.94* 0.94* 0.92* 0.6
Adenoma –
Hemangioma
0.8* 0.82* 0.9* 0.88* 0.87*
Adenoma –
HCC
0.97* 0.93* 0.67 0.64 0.52
Hemangioma –
HCC
0.86* 0.76* 0.83* 0.82* 0.8*
*denotes a statistically significant (p,0.05) areas under the curve values relative
to a random test (AUC= 0.5).
Bolded values denote AUC values significantly less than non-bolded values in a
given row.
HCC=Hepatocellular carcinoma.
FNH= Focal Nodular Hyperplasia.
ROC AUC=Receiver Operator Characteristic Area Under the Curve Values.
ADC=Apparent Diffusion Coefficient (mm2/s).
HB 1,2 =Hepatobiliary Phase (15 and 25 minutes post-contrast).
doi:10.1371/journal.pone.0061898.t002
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generally recommend the use of ER.
The utility of 25 minute versus 15 minute post-contrast
hepatobiliary imaging is also a topic not previously studied in
the literature to the knowledge of the authors. Previous authors
have suggested 10–25 minutes post-contrast as the standard time
point for hepatobiliary phase imaging with gadoxetic acid [16,17].
In this study, no significant advantages of later phase hepatobiliary
imaging (25 minutes post-contrast) were demonstrated in the
identification of any particular lesion or differentiation between
any two lesions. Reliance solely on 15 minute post-contrast
hepatobiliary phase imaging with gadoxetic acid may improve
practice throughput with the agent, a potential advantage of this
compound over the other commonly utilized hepatocyte-specific
contrast agent—gadobenate dimeglumine—with which hepato-
biliary phase imaging is often performed with delays of up to 90–
120 minutes [14,18].
Previous studies have examined the benefit of DWI MR in the
characterization of focal hepatic lesions: visual and quantitative
assessments with DWI have been found useful in distinguishing
hepatic hemangiomas and cysts from malignant hepatic lesions
[3,6,19]; although, there is considerable overlap between the ADC
values of solid benign (i.e. FNH and adenoma) and malignant
lesions [5]. Differentiating hemangiomas from other focal hepatic
lesions with gadoxetic acid enhanced MR has proven somewhat
problematic in prior works: studies have suggested the lack of a
true equilibrium phase with gadoxetic acid results in apparent
early washout (i.e. pseudowashout) with hemangiomas [20,21]. In
fact, the early-phase parameter with the quantitatively greatest
AUC value for hemangioma detection in our study was pre-
contrast CR, which reflects that quantified measures of contrast
enhancement are not helpful for the characterization of heman-
giomas. Hemangiomas could rather be differentiated best on basis
of quantitative measures using ADC values., which have been
shown in this study as a way to improve upon these potential
limitations of gadoxetic acid enhanced MRI. Although, ADC
values were more accurate than ER values in distinguishing
between hemangiomas and non-hemangiomas, there was no
statistical difference in accuracy between ADC and CR values in
this regard. In terms of pair-wise comparisons, ADC values did not
significantly differ from hepatobiliary CR or ER values in
accuracy. Results herein are consistent with prior works showing
increased ADC values with hemangiomas relative to the other
evaluated hepatic lesions; however, it is not clear if such values
offer improved characterization of hemangiomas versus hepato-
biliary phase imaging.
Limitations of this study include the inherent weaknesses
associated with retrospective analyses. In particular, not all hepatic
lesions were included in the analysis. Metastatic lesions were
excluded because they have several diagnostic drawbacks: first,
their small size results in partial volume effects deteriorating
quality of quantified measures. Second, in retrospective analysis
metastatic lesions would in many cases already be undergoing
adjuvant chemotherapy treatment which could alter enhancement
characteristics. Finally, metastases from different primary tumors
exhibit different early-phase enhancement characteristics render-
ing results difficult to generalize.
A relatively small number of lesions assessed herein were
confirmed histopathologically; unfortunately, this limitation is
necessary to some extent as histological confirmation of benign
hepatic lesions is typically not clinically necessary and thus
unethical given the risks of biopsy to the patient. For differenti-
ation of some lesions, this poses a particular problem. For
example, even with long-term clinical follow-up and assessment of
all available MRI sequences, it may be difficult or impossible to
distinguish hepatic adenomas from FNH in certain cases. A recent
study by Grazioli et al reported, with some heterogeneity,
hypointensity of hepatic adenomas to parenchyma in the
hepatobiliary phase [22]. Of note, the majority (6 of 10) of
adenomas in our work were hypointense to hepatic parenchyma in
the HB phase, and FNH and adenomas were accurately
distinguished on the basis of CRs. The relatively greater degree
of HB ER with adenomas observed herein (although, still less than
mean FNH ER) may be due to the relatively low number of
adenomas included in this study and/or reflect a greater
proportion of ‘‘unclassified subtype’’ lesions, which are less likely
to be hypointense in the HB phase [22]. It is possible that
inaccurate clinical characterization of some adenomas as FNH’s
and vice versa could to contribute to this as well. Furthermore, the
relative lack of cases with histopathological correlation poses a
potential limitation with respect to evaluation of HCC with
gadoxetic acid contrast-enhanced MRI. Specifically, a recent
study by Kim et al revealed a greater degree of hepatobiliary phase
enhancement in well-differentiated relative to moderately and
poorly differentiated HCC [23]. As detailed assessment of HCC
grade was not able to be performed in our work, the effect of HCC
Table 3. Cutoff values for quantitative enhancement
parameters in the differentiation of HCC from other solitary
hepatic lesions.
Optimal Cutoff SS(%) SP(%)
HB1 ER* 0.16 87.2 94.4
HB2 ER* 0.57 87.2 88.9
HB1 CR 0.49 88.9 38.5
HB2 CR 0.58 83.3 43.6
ADC (mm2/s) 1.19*1023 61 87.2
*Denotes measures recommended quantitative parameter for this evaluation.
SS – Sensitivity.
SP– Specificity.
ER – enhancement ratio.
CR – contrast ratio.
HB 1,2 =Hepatobiliary Phase (15 and 25 minutes post-contrast).
doi:10.1371/journal.pone.0061898.t003
Table 4. Maximum sensitivity (SS) and specificity (SP) values
obtainable with quantitative conventional and hepatobiliary
phase enhancement parameters.
Lesion Parameter SS (%) SP (%)
HCC ER venous 94 62
ER HB 94 87
FNH CR venous 100 67
ER HB 100 78
Hemangioma CR pre-contrast 91 89
CR HB 76 89
Adenoma CR portal-venous 70 72
ER HB 90 67
ER – enhancement ratio.
CR – contrast ratio.
HB – hepatobiliary phase.
HCC=Hepatocellular carcinoma.
FNH= Focal Nodular Hyperplasia.
doi:10.1371/journal.pone.0061898.t004
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differentiation on our results is not known. It is possible that
hepatobiliary phase imaging with gadoxetic acid would more
accurately distinguish moderate and poorly differentiated HCC
from the benign entities demonstrating increased hepatobiliary
enhancement in this work (i.e. FNH and hepatic adenomas),
whereas differentiation between these entities and well-differenti-
ated HCC may prove more difficult. Finally, addition of
qualitative parameters in the assessment of the liver lesions would
likely aid in diagnostic accuracy. For example, a ring-enhance-
ment pattern on gadoxetic acid contrast-enhanced MR has been
shown to make the diagnosis of hemangioma less likely [21].
However, such qualitative assessments are inherently subjective. A
radiologist may utilize a purely quantitative measure to gain
objective data regarding a solitary hepatic lesion. In this case,
knowledge of the relative diagnostic accuracy of the CR and ER
values presented herein provide the practicing radiologist with
quantitative data which can be synthesized with the qualitative
interpretation to make a more confident diagnosis. In the case
when a radiologist has narrowed the considerations between two
focal lesions, pair-wise parameters may help determine between
them.
In summary, quantified analysis of gadoxetic acid contrast-
enhanced MR characterizes commonly encountered focal hepatic
lesions more accurately than ADC values. Hepatobiliary phase
imaging outperforms early dynamic imaging in the differentiation
between HCC and non-HCC. Utilization of enhancement ratio
values to characterize lesions is generally recommended over CR
values.
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